About
XoNovo is a preclinical-stage biopharmaceutical company engaged in the development of small-molecule therapeutics for preventing the progressive loss of neuronal function across multiple neurodegenerative diseases. The company's short-term focus is on its lead drug, XN001, in support of filing an investigational new drug application for Batten disease (BD), also known as neuronal ceroid lipofuscinoses, a fatal neurodegenerative orphan disorder. XoNovo utilizes a novel approach of selective modulation of autophagy and axonal transport machinery in neurons. XN001 has been extensively tested in both in-vitro and in-vivo models, showing promising results in neurodegenerative diseases including BD, Alzheimer's disease, glioblastoma, muscular dystrophy, and tuberous sclerosis.
Funding history · 1 round · — total
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- What is XoNovo's primary focus in drug development?
- XoNovo is a preclinical-stage biopharmaceutical company focused on developing small-molecule therapeutics to prevent the progressive loss of neuronal function in neurodegenerative diseases. Their lead drug, XN001, is being developed for Batten disease (BD).
- When was XoNovo founded?
- XoNovo was founded in August 2013.
- What is the current operational status of XoNovo?
- XoNovo is currently inactive, having ceased operations in September 2019.
- Which company did XoNovo partner with in September 2018?
- In September 2018, XoNovo entered into a service-based partnership with Inoviem Scientific.
- What was XoNovo's former name?
- XoNovo was formerly known as FutuRx.
- How many employees did XoNovo have?
- XoNovo had an employee count in the range of 11-50, with an exact count of 2 employees.
- Where is XoNovo's headquarters located?
- XoNovo's headquarters is located at Ilan Ramon Street 2, Ness Ziona, Israel.
- What is XoNovo's lead drug candidate and its primary target indication?
- XoNovo's lead drug candidate is XN001, primarily focused on Batten disease (BD), also known as neuronal ceroid lipofuscinoses.